---
title: "Abpro (ABP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/ABP.US.md"
symbol: "ABP.US"
name: "Abpro"
industry: "生物技术"
---

# Abpro (ABP.US)

| Item | Detail |
|------|--------|
| Industry | 生物技术 |

## Company Profile

Abpro Holdings, Inc.是一家生物技术公司，专注于用于免疫肿瘤学和眼科的创新抗体构建。其平台包括 DiversImmune，这是一个发现平台，能够生成针对临床验证和新靶点的多样化专有抗体集合；以及 MultiMab，这是一个工程平台，提供灵活性以不同组合和方向组合抗体构建模块，创造适合目的的新型全长多特异性抗体构建。该公司的主要产品候选包括 ABP-102，这是一种针对 HER2 和 CD3 的下一代免疫肿瘤学 TetraBi 抗体，旨在治疗 HER2+ 实体肿瘤，包括乳腺癌和胃癌；以及 ABP-201，这是一种 TetraBi 抗体格式，能够同时抑制 VEGF 和 ANG-2...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-03-01T04:30:12.000Z

**Overall: E (0.81)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 405 / 406 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% |  |
| Net Profit YoY | -185.64% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 0.00 |  |


**Multi Score**: E

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 42.31% | A |
| Profit Margin | 0.00% | D |
| Gross Margin | 0.00% | E |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -100.00% | E |
| Net Profit YoY | -185.64% | E |
| Total Assets YoY | -49.54% | E |
| Net Assets YoY | -31.03% | E |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 0.00% | C |
| OCF YoY | -100.00% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 1015.74% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Abpro",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "42.31%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "0.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-100.00%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-185.64%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-49.54%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-31.03%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "0.00%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "-100.00%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "1015.74%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 02 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 03 | MiMedx (US.MDXG) | A | B | A | B | B | A |
| 04 | Rigel制药 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.06 | 80/606 | - | - | - |
| PB | -0.09 | 460/606 | - | - | - |
| PS (TTM) | 80.02 | - | 92.08 | 80.02 | 72.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/ABP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/ABP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/ABP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.